Clovis Oncology Inc Could Decline a Lot According to The Today’s Call Option Activity

 Clovis Oncology Inc Could Decline a Lot According to The Today's Call Option Activity

In today’s session Clovis Oncology Inc (CLVS) recorded an unusually high (713) contracts volume of put trades. Someone, most probably a professional was a very active buyer of the November, 2016 put, expecting serious CLVS decrease. With 713 contracts traded and 10764 open interest for the Nov, 16 contract, it seems this is a quite bearish bet. The option with symbol: CLVS161118P00025000 closed last at: $0.95 or 5.6% up. About 567,623 shares traded hands. Clovis Oncology Inc (NASDAQ:CLVS) has risen 48.59% since March 31, 2016 and is uptrending. It has outperformed by 46.07% the S&P500.

Analysts await Clovis Oncology Inc (NASDAQ:CLVS) to report earnings on November, 3. They expect $-1.93 EPS, up 26.34% or $0.69 from last year’s $-2.62 per share. After $-2.07 actual EPS reported by Clovis Oncology Inc for the previous quarter, Wall Street now forecasts -6.76% EPS growth.

Clovis Oncology Inc (NASDAQ:CLVS) Ratings Coverage

Out of 9 analysts covering Clovis Oncology (NASDAQ:CLVS), 4 rate it a “Buy”, 1 “Sell”, while 4 “Hold”. This means 44% are positive. Clovis Oncology has been the topic of 24 analyst reports since September 10, 2015 according to StockzIntelligence Inc. The firm earned “Neutral” rating on Wednesday, August 24 by Mizuho. The firm earned “Buy” rating on Thursday, September 10 by WallachBeth Capital. The firm earned “Neutral” rating on Monday, April 4 by Piper Jaffray. On Wednesday, September 21 the stock rating was upgraded by Credit Suisse to “Outperform”. The firm has “Buy” rating by Suntrust Robinson given on Wednesday, August 24. The rating was maintained by Stifel Nicolaus on Friday, February 26 with “Buy”. As per Thursday, January 21, the company rating was initiated by Credit Suisse. The stock has “Sell” rating given by Chardan Capital Markets on Tuesday, October 25. The rating was maintained by Suntrust Robinson with “Buy” on Friday, September 23. Mizuho downgraded Clovis Oncology Inc (NASDAQ:CLVS) rating on Monday, November 16. Mizuho has “Neutral” rating and $35 price target.

According to Zacks Investment Research, “Clovis Oncology Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents in the United States, Europe and additional international markets. The Company targets its development programs for the treatment of specific subsets of cancer populations. Clovis Oncology Inc. is headquartered in Colorado, USA.”

Insitutional Activity: The institutional sentiment increased to 1 in Q2 2016. Its up 0.13, from 0.87 in 2016Q1. The ratio is positive, as 36 funds sold all Clovis Oncology Inc shares owned while 26 reduced positions. 18 funds bought stakes while 44 increased positions. They now own 36.50 million shares or 0.57% less from 36.71 million shares in 2016Q1.
Blackrock has 117,450 shares for 0% of their US portfolio. Blackrock Fund Advsr, a California-based fund reported 1.27M shares. Secor Advsrs L P holds 0.02% or 14,081 shares in its portfolio. Ubs Asset Mngmt Americas reported 12,289 shares or 0% of all its holdings. The United Kingdom-based Legal & General Grp Incorporated Public Ltd Com has invested 0% in Clovis Oncology Inc (NASDAQ:CLVS). Nelson Van Denburg And Campbell Wealth Mngmt Ltd Com last reported 0% of its portfolio in the stock. Alliancebernstein L P last reported 46,340 shares in the company. Geode Cap Mgmt Ltd Liability Corporation reported 227,024 shares or 0% of all its holdings. Two Sigma Secs Limited Co last reported 0.08% of its portfolio in the stock. Great West Life Assurance Communications Can last reported 0% of its portfolio in the stock. Boston Partners reported 112,211 shares or 0% of all its holdings. Wolverine Asset Mgmt Ltd Liability Co owns 10,584 shares or 0% of their US portfolio. Profund Advsrs Ltd Liability Co has 0.01% invested in the company for 19,227 shares. Royal National Bank Of Canada holds 0% of its portfolio in Clovis Oncology Inc (NASDAQ:CLVS) for 18,212 shares. Renaissance Techs Ltd reported 307,200 shares or 0.01% of all its holdings.

Clovis Oncology, Inc. is a biopharmaceutical firm focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The company has a market cap of $1.05 billion. The Firm is developing approximately three product candidates: Rociletinib, Rucaparib and Lucitanib. It currently has negative earnings. Rociletinib is an oral epidermal growth factor receptor , mutant-selective covalent inhibitor that is under review with the United States and European regulatory authorities for the treatment of non-small cell lung cancer (NSCLC) in patients with activating EGFR mutations, as well as the resistance mutation, T790M.

CLVS Company Profile

Clovis Oncology, Inc., incorporated on April 20, 2009, is a biopharmaceutical firm focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Firm is developing approximately three product candidates: Rociletinib, Rucaparib and Lucitanib. Rociletinib is an oral epidermal growth factor receptor (EGFR), mutant-selective covalent inhibitor that is under review with the United States and European regulatory authorities for the treatment of non-small cell lung cancer (NSCLC) in patients with activating EGFR mutations, as well as the resistance mutation, T790M. Rucaparib is an oral inhibitor of poly (ADP-ribose) polymerase (PARP) that is in advanced clinical development for the treatment of ovarian cancer. Lucitanib is an oral inhibitor of the tyrosine kinase activity of vascular endothelial growth factor receptors 1-3 (VEGFR1-3) and platelet-derived growth factor receptors alpha and beta (PDGFR a/b).

More notable recent Clovis Oncology Inc (NASDAQ:CLVS) news were published by: Fool.com which released: “Why Clovis Oncology Inc. Rose 52.7% in September” on October 10, 2016, also Businesswire.com with their article: “Clovis Oncology to Present at the 2016 Credit Suisse Healthcare Conference” published on October 31, 2016, Fool.com published: “Why Clovis Oncology Shares Are Falling 14.5% Today” on October 07, 2016. More interesting news about Clovis Oncology Inc (NASDAQ:CLVS) were released by: Finance.Yahoo.com and their article: “Clovis Oncology to Announce Third Quarter 2016 Financial Results and Host …” published on October 27, 2016 as well as Schaeffersresearch.com‘s news article titled: “Analyst Update: Clovis Oncology Inc, Calithera Biosciences Inc, and Gilead …” with publication date: October 25, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment